Johnson & Johnson Receives Subpoenas On Marketing Of Risperdal, Topamax and Natrecor
This article was originally published in The Pink Sheet Daily
Executive Summary
Subpoenas relate to investigations into sales and marketing practices by U.S. Attorneys in Philadelphia, Boston and San Francisco.
You may also be interested in...
Lilly, AstraZeneca, Cephalon Marketing Practices Under Review By House Committee
Rep. Waxman is requesting information into the marketing of Zyprexa, Seroquel, Actiq and Fentora.
Effexor Latest Target Of U.S. Office Of Personnel Management Investigation Into Rx Marketing
OPM appears to be conducting a wide-ranging investigation into mental health drug marketing. Forest, J&J and Wyeth have received subpoenas from the agency that oversees Federal Employees Health Benefits Program.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.